Bladder dysfunction in Parkinsonism: Mechanism, prevalence, symptoms, and management

Movement Disorders

Volumn 21, Issue 6, 2006, Pages 737-745

  Winge, Kristian ^a   Fowler, Clare J ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Bladder control; Dopamine receptors; Functional imaging; Parkinsonism; Urinary symptoms

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; LEVODOPA; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PERGOLIDE; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLADDER ASPIRATION; BLADDER CATHETERIZATION; BLADDER DYSFUNCTION; BLADDER FUNCTION; BLADDER SPHINCTER; BLADDER SURGERY; BRADYKINESIA; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; CORRELATION ANALYSIS; CYSTOMETRY; DETRUSOR MUSCLE; DOPAMINERGIC ACTIVITY; HUMAN; HYPOTENSION; IMPAIRED BLADDER EMPTYING; INDWELLING CATHETER; MEDICAL DECISION MAKING; MICTURITION; NEUROGENIC BLADDER; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SHY DRAGER SYNDROME; SYMPTOM; UNSPECIFIED SIDE EFFECT; URETHROGRAPHY; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS;

BRAIN; HUMANS; PARKINSON DISEASE; PREVALENCE; URINARY BLADDER; URINARY BLADDER DISEASES; URINARY BLADDER, NEUROGENIC; URINATION DISORDERS;

EID: 33745847810     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20867     Document Type: Review

References (108)

1. Winge K, Fowler CJ. Scientific evidence and expert clinical opinion for the investigation and management of incontinence and sexual dysfunction. In: Findley L, Hurwitz B, Miles A, editors. The effective management of Parkinson's disease. London: Aesculapius Medical Press; 2004. p 149-156.
2. Blok BF, Holstege G. The central control of micturition and continence: implications for urology. Br J Urol Int 1999; 83(Suppl. 2):1-6.
3. International Federation of Associations of Anatomists. Terminologia anatomica: international anatomical terminology. Stuttgart: Thieme; 1998.
4. Blok BF, Willemsen AT, Holstege G. A PET study on brain control of micturition in humans. Brain 1997;120(Pt. 1):111-121.
5. Blok BF, Sturms LM, Holstege G. Brain activation during micturition in women. Brain 1998;121(Pt. 11):2033-2042.
6. Nour S, Svarer C, Kristensen JK, Paulson OB, Law I. Cerebral activation during micturition in normal men. Brain 2000;123(Pt. 4):781-789.
7. Athwal BS, Berkley KJ, Hussain I, et a]. Brain responses to changes in bladder volume and urge to void in healthy men. Brain 2001;124:369-377.
8. Blok BF. Central pathways controlling micturition and urinary continence. Urology 2002;59:13-17.
9. Blok BF, Holstege G. Ultrastructural evidence for a direct pathway from the pontine micturition center to the parasympathetic preganglionic motoneurons of the bladder of the cat. Neurosci Lett 1997;222:195-198.
10. Matsumoto G, Hisamitsu T, De Groat WC. Role of glutamate and NMDA receptors in the descending limb of the spinobulbospinal micturition reflex pathway of the rat. Neurosci Lett 1995;183:58-61.
11. Blok BF, van Maarseveen JT, Holstege G. Electrical stimulation of the sacral dorsal gray commissure evokes relaxation of the external urethral sphincter in the cat. Neurosci Lett 1998;249:68-70.
12. Blok BF, de Weerd H, Holstege G. The pontine micturition center projects to sacral cord GABA immunoreactive neurons in the cat. Neurosci Lett 1997;233:109-112.
13. Sie JA, Blok BF, de Weerd H, Holstege G. Ultrastructural evidence for direct projections from the pontine micturition center to glycine-immumoreactive neurons in the sacral dorsal gray commissure in the cat. J Comp Neurol 2001;429:631-637.
14. Holstege G, Griffiths D, de Wall H, Dalm E. Anatomical and physiological observations on supraspinal control of bladder and urethral sphincter muscles in the cat. J Comp Neurol 1986;250: 449-461.
15. Blok BF, Holstege G. The central nervous system control of micturition in cats and humans. Behav Brain Res 1998;92:119-125.
16. Blok BF, de Weerd H, Holstege G. Ultrastructural evidence for a paucity of projections from the lumbosacral cord to the pontine micturition center or M-region in the cat: a new concept for the organization of the micturition reflex with the periaqueductal gray as central relay. J Comp, Neurol 1995;359:300-309.
17. Blok BF, Holstege G. Direct projections from the periaqueductal gray to the pontine micturition center (M-region): an anterograde and retrograde tracing study in the cat. Neurosci Lett 1994;166: 93-96.
18. Kruse MN, Noto H, Roppolo JR, De Groat WC. Pontine control of the urinary bladder and external urethral sphincter in the rat. Brain Res 1990;532:182-190.
19. Hashimoto K, Oyama T, Sugiyama T, Park YC, Kurita T. Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D(1) and D(2) receptors in rats. J Pharmacol Sci 2003;92:143-148.
20. Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001;20:105-113.
21. Holstege G. Descending motor pathways and the spinal motor system: limbic and non-limbic components. Prog Brain Res 1991; 87:307-421.
22. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defaecation. Brain 1964;87:233-262.
23. De Groat WC. Neural control of the urinary bladder and sexual organs. In: Mathias CJ, Bannister R, editors. Autonomic failure. New York: Oxford University Press; 1999. p 151-165.
24. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
25. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-116.
26. Winge K, Rasmussen D, Werdelin LM. Constipation in neurological diseases. J Neurol Neurosurg Psychiatry 2003;74:13-19.
27. Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, Montastruc JL. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-589.
28. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord 2003;10:23-28.
29. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
30. Mathias CJ. Neurodegeneration, parkinsonian syndromes and autonomic failure. Auton Neurosci 2002;96:50-58.
31. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-316.
32. Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system disorders. In: Koller WC, editor. Handbook of Parkinsons disease. New York: Marcel Dekker; 1987. p 145-170.
33. Hald T, WE B. The urinary bladder, neurology and dynamics. Baltimore, MD: Williams and Wilkins; 1982.
34. Andersen JT. Disturbances of bladder and urethral function in Parkinson's disease. Int Urol Nephrol 1985;17:35-41.
35. Porter RW, Bors E. Neurogenic bladder in parkinsonism: effect of thalamotomy. J Neurosurg 1971;34:27-32.
36. Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson's disease. J Urol 1987;138:836-838.
37. Hattori T, Yasuda K, Kita K, Hirayama K. Voiding dysfunction in Parkinson's disease. Jpn J Psychiatry Neurol 1992;46:181-186.
38. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson's disease. J Urol 1983;129:80-83.
39. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000;68:429-433.
40. Campos-Sousa RN, Quagliato E, da Silva BB, De CR Jr, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 2003;61:359-363.
41. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76-85.
42. Lemack GE, Dewey RB, Roehrborn CG, O'Suilleabhain PE, Zimmern PE. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000;56:250-254.
43. Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Ageing 1995;24:499-504.
44. Aranda B, Perrigot M, Mazieres L, Pierrot-Deseilligny E. Bladder sphincter disorders in Parkinson's disease. Rev Neurol (Paris) 1983;139:283-288.
45. Dmochowski RR. Female voiding dysfunction and movement disorders. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:144-151.
46. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001;49:313-319.
47. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996;47:160-166.
48. Galloway NT. Urethral sphincter abnormalities in parkinsonism. Br J Urol 1983;55:691-693.
49. Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, Milroy EJ. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-1453.
50. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 2000;164:1640-1643.
51. Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 1993;32:315-321.
52. Yoshimura N, Mizuta E, Yoshida O, Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 1998;286:228-233.
53. Yoshimura N, Kuno S, Chancellor MB, De Groat WC, Seki S. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol 2003;139:1425-1432.
54. Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 2001;187:55-59.
55. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005;12:842-850.
56. Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 1993;12:203-209.
57. Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson's disease. Br J Urol 1985;57:652-656.
58. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003;18:573-578.
59. Winge K, Werdelin LM, Krøyer K, Stimpel H. Bladder dysfunction in young patients with Parkinson's disease. Mov Disord 2002;17(Suppl. 5):S218.
60. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 2004;23:689-696.
61. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord 2002;17:775-781.
62. Van Kerrebroeck P, Abrams P, Chaikin D, et al, The standardisation of terminology in nocturia: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002;21:179-183.
63. Duchesne N, Soucy JP, Masson H, Chouinard S, Bedard MA. Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123iodine-beta-CIT in patients on and off levodopa. Clin Neuropharmacol 2002;25:216-224.
64. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002;51:156-164.
65. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-932.
66. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001;71:600-606.
67. Winge K, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinson's disease. Mov Disord 2005; 20(Suppl. 10):S102.
68. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.
69. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57:1497-1499.
70. Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 1992;32:134-140.
71. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994;151:1336-1341.
72. Kirby R, Fowler C, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986;49:554-562.
73. Sakakibara R, Hattori T, Tojo M, Yamanishi T, Yasuda K, Hirayama K. Micturitional disturbance in multiple system atrophy. Jpn J Psychiatry Neurol 1993;47:591-598.
74. Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, Yamanishi T. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 2000;68:65-69.
75. Tison F, Arne P, Sourgen C, Chrysostome V, Yeklef F. The value of external anal sphincter electromyography for the diagnosis of multiple system atrophy. Mov Disord 2000;15:1148-1157.
76. Stocchi F, Carbone A, Inghilleri M, Monge A, Ruggieri S, Berardelli A, Manfredi M. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997;62:507-511.
77. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997;80:100-104.
78. Burn DJ, Jaros E. Multiple system atrophy: cellular and molecular pathology. Mol Pathol 2001;54:419-426.
79. Wenning GK, Geser F, Stampfer-Kountchev M, Tison F. Multiple system atrophy: an update. Mov Disord 2003;18(Suppl. 6):S34-S42.
80. Sakakibara R, Hattori T, Tojo M, Yamanishi T, Yasuda K, Hirayama K. Micturitional disturbance in progressive supranuclear palsy. J Auton Nerv Syst 1993;45:101-106.
81. Wakatsuki A, Tsujihata M, Miyake O, Ito H, Itatani H, Udaka F. Comparison of the vesicourethral function between progressive supranuclear palsy and Parkinson's disease. Hinyokika Kiyo 1993;39:523-528.
82. Sakakibara R, Uchiyama T, Yamanishi T, Hattori T. Urinary function in patients with corticobasal degeneration: comparison with normal subjects. Neurourol Urodyn 2004;23:154-158.
83. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinson's disease. Neurourol Urodyn 2006;DOI 10.1002/nau.20193.
84. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000;55:51-57.
85. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50:90-96.
86. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177-184.
87. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-644.
88. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27:144-153.
89. Yamamoto M. Pergolide improves neurogenic bladder in patients with Parkinson's disease. Mov Disord 1997;12:328.
90. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
91. Finazzi-Agro E, Peppe A, d'Amico A, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol 2003;169:1388-1391.
92. Seif C, Herzog J, van der HC, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55:118-120.
93. Dalmose AL, Bjarkam CR, Sorensen JC, Djurhuus JC, Jorgensen TM. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourol Urodyn 2004;23:265-272.
94. Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? a comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000;79:191-195.
95. Blok BF. Brain control of the lower urinary tract. Scand J Urol Nephrol 2002;(Suppl.):11-15.
96. Gjone R. Excitatory and inhibitory bladder responses to stimulation of "limbic," diencephalic and mesencephalic structures in the cat. Acta Physiol Scand 1966;66:91-102.
97. Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats. Auton Neurosci 2002;102:30-38.
98. Yoshimura N, Sasa M, Yoshida O, Takaori S. Dopamine D-1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia-nigra. Neurourol Urodyn 1992;11:535-545.
99. Hashimoto K, Oyama T, Ukay Y, Kimura K, Sugiyama T, Park YC, Kurita T. Selective destruction of dopamine neurones of the ventral tegmental area, but not the substantia nigra, impairs reflex micturition in rats. Neurourol Urodyn 1997;16:470-471.
100. Matsuura S, Downie JW, Allen GV. Micturition evoked by glutamate microinjection in the ventrolateral periaqueductal gray is mediated through Barrington's nucleus in the rat. Neuroscience 2000;101:1053-1061.
101. Noto H, Roppolo JR, Steers WD, De Groat WC. Electrophysiological analysis of the ascending and descending components of the micturition reflex pathway in the rat. Brain Res 1991;549:95-105.
102. Matsuura S, Kakizaki H, Mitsui T, Shiga T, Tamaki N, Koyanagi T. Human brain region response to distention or cold stimulation of the bladder: a positron emission tomography study. J Urol 2002;168:2035-2039.
103. Bruggemann J, Vahle-Hinz C, Kniffki KD. Representation of the urinary bladder in the lateral thalamus of the cat. J Neurophysiol 1993;70:482-491.
104. Bruggemann J, Shi T, Apkarian AV. Squirrel monkey lateral thalamus: II, viscerosomatic convergent representation of urinary bladder, colon, and esophagus. J Neurosci 1994;14:6796-6814.
105. Bruggemann J, Shi T, Apkarian AV. Viscero-somatic neurons in the primary somatosensory cortex (SI) of the squirrel monkey. Brain Res 1997;756:297-300.
106. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985;35:1215-1218.
107. Gombart L, Soares J, Alexander GE. Functional anatomy of basal ganglia and motor systems. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 2004. p 87-100.
108. Wichmann T, DeLong MR. Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 2004. p 101-112.